02675 精鋒醫療－Ｂ
EDGE MEDICAL-B
EDGE MEDICAL-B
| Register Close | 2026/01/05 IPO Closing in 4 Days |
| Listing Date | 2026/01/08 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Shenzhen Edge Medical Co. was founded in 2017, it is an advanced surgical robot company in the medical device industry, dedicated to designing, developing and manufacturing surgical robots.
--
The Group has a pipeline of three products and product candidates covering various models at different development stages to capture the market potential in surgical robots, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots for minimally invasive surgery (“MIS”), as well as natural orifice surgical robots for non invasive surgery.
--
The Group’s product portfolio comprises two self-developed Core Products: Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot. The Group’s product portfolio also includes Edge Bronchoscope Robot, which is not a Core Product.
--
The Group has entered into agreements for sales of 61 units of its Core Products globally as of June 30, 2025. As of December 21, 2025, over 12,000 and 2,000 cases of robot assisted clinical surgeries in China were completed using the Group’s Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot, respectively. The Group had 453 issued patents and 213 patent applications in China.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 27.72M H shares |
| No. of International Offer Shares | 24.95M H shares |
| No. of HK Offer Shares | 2.77M H shares |
| Offer Price | $43.24 |
| Stock Code | 2675 |
| Sponsor(s) | Morgan Stanley Asia Limited, GF Capital (Hong Kong) Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, GF Securities (Hong Kong) Brokerage Limited, China International Capital Corporation Hong Kong Securities Limited, CLSA Limited, CMBC Securities Company Limited |
TIME TABLE
| Application Period | Dec 30 (Tue) - noon, Jan 05 (Mon) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jan 07 (Wed) |
| Result Announcement Date | On or before Jan 07 (Wed) |
| Result Announcement Date | On or before Jan 08 (Thu) |
| Dealings in Shares commence on | Jan 08, 2026. (Thu) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $43.24 |
| Capitalization (H Shares) | 13.99B |
| NAV / share ($) | $6.3 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 43.24, the net proceeds raised would be HKD 1.12B, of which |
| 23% : Ongoing and planned R&D of Edge Multi-Port Endoscopic Surgical Robot |
| 19% : Ongoing and planned R&D of Edge Single-Port Endoscopic Surgical Robot |
| 20% : Commercialization of Core Products |
| 10% : Expansion of manufacturing capacity |
| 8% : Allocated to other products and product candidates |
| 10% : For potential strategic acquisitions, investments or collaborations in the surgical robot industry and related fields |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).